Format
Sort by

Send to

Choose Destination

Search results

Items: 15

1.

Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.

Brinton EA, Kher U, Shah S, Cannon CP, Davidson M, Gotto AM, Ashraf TB, McCrary Sisk C, Dansky H, Mitchel Y, Barter P; DEFINE Investigators.

J Clin Lipidol. 2015 Jan-Feb;9(1):65-71. doi: 10.1016/j.jacl.2014.10.005. Epub 2014 Nov 4.

PMID:
25670362
2.

Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus.

Dunkler D, Dehghan M, Teo KK, Heinze G, Gao P, Kohl M, Clase CM, Mann JF, Yusuf S, Oberbauer R; ONTARGET Investigators.

JAMA Intern Med. 2013 Oct 14;173(18):1682-92.

PMID:
23939297
3.

Safety of anacetrapib in patients with or at high risk for coronary heart disease.

Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P; Determining the Efficacy and Tolerability Investigators.

N Engl J Med. 2010 Dec 16;363(25):2406-15. doi: 10.1056/NEJMoa1009744. Epub 2010 Nov 17.

4.

Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.

Cannon CP, Dansky HM, Davidson M, Gotto AM Jr, Brinton EA, Gould AL, Stepanavage M, Liu SX, Shah S, Rubino J, Gibbons P, Hermanowski-Vosatka A, Binkowitz B, Mitchel Y, Barter P; DEFINE investigators.

Am Heart J. 2009 Oct;158(4):513-519.e3. doi: 10.1016/j.ahj.2009.07.028.

PMID:
19781408
5.

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P.

Lancet. 2008 Sep 27;372(9644):1174-83. doi: 10.1016/S0140-6736(08)61242-8. Epub 2008 Aug 29. Erratum in: Lancet. 2008 Oct 18;372(9647):1384.

PMID:
18757085
6.

Telmisartan, ramipril, or both in patients at high risk for vascular events.

ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C.

N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31.

7.

Early management of myocardial infraction: a report from the Waikato Hospital, New Zealand.

Ong HT, Friedlander DH.

Singapore Med J. 1991 Oct;32(5):373-5.

PMID:
1686333
8.

Cholesterol atheroembolism: an increasingly frequent complication of cardiac catheterisation.

Ong HT, Elmsly WG, Friedlander DH.

Med J Aust. 1991 Mar 18;154(6):412-4.

PMID:
2000056
9.

The congenital long QT syndrome.

Friedlander DH, Pullon DH.

N Z Med J. 1989 Nov 22;102(880):620-1. No abstract available.

PMID:
2594288
10.

Idiopathic infantile arterial calcification with survival to adult life.

Marrott PK, Newcombe KD, Becroft DM, Friedlander DH.

Pediatr Cardiol. 1984 Apr-Jun;5(2):119-22.

PMID:
6473121
11.
12.

Acute coronary artery disease and oral contraceptives.

Friedlander DH, Snell AP.

Aust N Z J Med. 1975 Feb;5(1):12-6.

PMID:
1057908
13.

Preparation of a patient with cardiovascular disease for surgery.

Friedlander DH.

N Z Med J. 1973 Nov 28;78(503):444-8. No abstract available.

PMID:
4149713
14.

A guide to safe and effective digitalis therapy.

Friedlander DH.

Drugs. 1972;3(5):404-13. No abstract available.

PMID:
4652595
15.

Clinical experiences with propranolol.

Besterman EM, Friedlander DH.

Postgrad Med J. 1965 Sep;41(479):526-35. No abstract available.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk